Almac Group records highest ever revenue, profit and employee numbers as $250 million global expansion plans announced

Almac Group records highest ever revenue, profit and employee numbers as $250 million global expansion plans announced

Almac Group, the global contract pharmaceutical development and manufacturing organisation, has today reported its highest ever end-of-year results for revenue, profit and employee numbers.   

In their financial results for year ending 30 September 2021*, Almac recorded a $79 million (8.6%) rise in revenue from $927 million in 2020 to $1.01 billion in 2021.  Pre-tax profits were recorded at $111 million, up from $87 million (27.1% increase) for the same period the previous year.  

The report also detailed an increase in Almac’s average employee figures from 5,466 to 5,783 (5.8%) during the period of October 2020 to September 2021. Current employee numbers for the Group now sits at over 6,500 and a current global recruitment drive will increase the total number to over 8,000 over the next three years.

Privately owned Almac is committed to reinvesting all profits back into its business— today announcing a $250 million global capital investment plan to meet increased client demand over the next three years.

Investment will take place in existing Almac locations in the United Kingdom, Europe, North America and Asia.  

Almac is at the forefront of developing, manufacturing, testing and distributing essential medicines to vulnerable patients around the world. During this financial year the group was involved in the development of over 300 life-saving drugs spanning more than 20 therapeutic areas including oncology, cardiology, immunology, gene therapy and neurology. Almac was also instrumental in supporting over 200 research projects for COVID-19 vaccines and treatments.

Alan Armstrong, Almac Group CEO, said: “I am hugely proud of our achievements in the last financial year. I am incredibly grateful to every one of our employees for their part in delivering these outstanding results as we continue our vital work developing life-saving and life-enhancing medicines for our clients and patients.

“Almac is committed to re-investing all profits back into the business to ensure we are market leading for clients and offer the best possible work environment for our people.  

“For our clients, we are investing $250 million on expansion to ensure we remain the global leaders in our industry and give them, and ultimately the patients across the globe who receive benefit from these therapeutics, the best possible offering from Almac.”